- Home
- NEGG vs MNKD Comparison
NEGG vs MNKD Comparison
Compare NEGG & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEGG | MNKD |
|---|---|---|
| Founded | 2001 | 1991 |
| Country | United States | United States |
| Employees | 762 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 883.1M | 793.6M |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | NEGG | MNKD |
|---|---|---|
| Price | $34.40 | $2.86 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $8.69 |
| AVG Volume (30 Days) | 60.9K | ★ 3.3M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $348,966,000.00 |
| Revenue This Year | N/A | $35.81 |
| Revenue Next Year | N/A | $11.89 |
| P/E Ratio | ★ N/A | $141.25 |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $3.40 | $2.23 |
| 52 Week High | $137.84 | $6.51 |
Technical Indicators
Market Signals| Indicator | NEGG | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 38.25 | 53.56 |
| Support Level | $30.58 | $2.52 |
| Resistance Level | $47.10 | $2.98 |
| Average True Range (ATR) | 3.30 | 0.13 |
| MACD | -0.61 | 0.05 |
| Stochastic Oscillator | 9.68 | 69.23 |
Price Performance
Historical ComparisonAbout NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.